Vivek Ra­maswamy launch­es yet an­oth­er Vant, this time in Asia with a TCR-fo­cused Medi­gene part­ner­ship

Vivek Ra­maswamy’s com­pa­ny-churn­ing shop Roivant is op­er­at­ing at full steam. Af­ter un­veil­ing Chi­nese bio­phar­ma up­start Sino­vant last year, the two en­ti­ties on Thurs­day de­buted a fresh cell ther­a­py com­pa­ny — Cy­to­vant Sci­ences — ded­i­cat­ed to the Asian mar­ket, armed with a part­ner­ship with Ger­many’s im­munother­a­py-fo­cused Medi­gene.

Un­der the deal, Medi­gene has grant­ed Cy­to­vant ex­clu­sive li­cens­es to de­vel­op, man­u­fac­ture, and com­mer­cial­ize Medi­gene’s re­search-stage T cell im­munother­a­py tar­get­ing New York esophageal squa­mous cell car­ci­no­ma (NY-ESO-1 ) — a well-known can­cer-testis anti­gen ex­pressed by var­i­ous can­cers — as well as a den­drit­ic cell vac­cine tar­get­ing leukemia-as­so­ci­at­ed anti­gens — WT-1 and PRAME —in Greater Chi­na, South Ko­rea, and Japan. Cy­to­vant and Medi­gene will al­so dis­cov­er and col­lab­o­rate on T-cell re­cep­tor (TCR) im­munother­a­pies for two ad­di­tion­al tar­gets, tai­lored specif­i­cal­ly to Asian pa­tients.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER